An interventional study of Difelikefalin Injection and Normal Saline (0.9% NaCl) in Itching Symptoms and CKD 5D, Hemodialysis, sponsored by Chittagong Medical College. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Chittagong Medical College · Not applicable, Interventional, and Treatment
A randomized, placebo-controlled, double-blind trial will be conducted in the Department of Nephrology at Chittagong Medical College Hospital, Chattogram, Bangladesh, over a period of one and a half years. A total of 102 patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis will be enrolled in the study.
Patients with moderate-to-severe pruritus, defined as a Worst Itching Intensity Numerical Rating Scale (WI-NRS) score ≥ 4, will be included. Eligible participants will be randomly assigned in a 1:1 ratio to receive either difelikefalin (0.5 mcg/kg) or placebo administered intravenously after each hemodialysis session for 6 weeks.
The primary outcome measure will be the change in WI-NRS score from baseline to week 6. Secondary outcomes will include changes in quality of life assessed using the Skindex-10 scale. Adverse events and safety parameters will also be monitored throughout the study period.
The primary analysis will be conducted using the intention-to-treat principle. A per-protocol analysis may also be performed as a secondary analysis. Statistical analysis will be carried out using SPSS version 27.
Chronic kidney disease-associated pruritus (CKD-aP), alternatively termed uremic pruritus (UP), represents a frequent, distressing, and often incapacitating clinical manifestation among individuals diagnosed with chronic kidney disease (CKD) or end-stage renal disease (ESRD). Characterized by persistent, intense itching-typically generalized but occasionally localized-CKD-aP disproportionately affects patients undergoing hemodialysis, with epidemiological studies reporting a variable prevalence ranging from 22% to 84% in this population. Notably, a substantial subset of these patients, approximately 20-40%, experience moderate-to-severe pruritus, which significantly diminishes their quality of life.
The impact of CKD-aP extends beyond physical discomfort. The condition is associated with chronic sleep disturbances such as insomnia, fatigue, and dermatological complications including excoriations, lichenification, and secondary infections due to repeated scratching. Psychosocially, patients often experience emotional distress, social withdrawal, and stigmatization related to visible skin lesions, which may worsen underlying mental health conditions such as anxiety and depression. Additionally, CKD-aP has been associated with increased mortality in dialysis patients, including higher risks of cardiovascular events and infections, suggesting a link with systemic inflammation and immune dysregulation.
There is a clear need for effective treatment options for CKD-aP. Current off-label therapies include antihistamines, topical corticosteroids, gabapentin, and pregabalin. While some of these treatments may reduce itching, their side effects can limit their use in this population.
The pathogenesis of CKD-aP remains incompletely understood. Proposed mechanisms include metabolic disturbances, immune system dysregulation, and imbalance in the endogenous opioid system, particularly involving peripheral kappa opioid receptors.
Difelikefalin is a peripherally acting, selective kappa opioid receptor agonist that exerts antipruritic effects through activation of receptors on peripheral neurons and immune cells. Its hydrophilic peptide structure limits its ability to cross the blood-brain barrier, thereby reducing central nervous system effects.
Difelikefalin has been approved as the first medication specifically indicated for CKD-aP in patients undergoing dialysis and has demonstrated efficacy in phase 3 clinical trials. It is currently recommended as a first-line treatment for moderate-to-severe CKD-aP in dialysis patients where available.
Despite promising results, some limitations remain. A proportion of patients do not achieve clinically meaningful improvement in itch intensity or quality of life. Clinical trials have demonstrated significant benefits, but response variability persists.
The safety profile of difelikefalin is dose-dependent. Common adverse effects include nausea, vomiting, dizziness, diarrhea, and gait disturbances. A dose of 0.5 μg/kg appears to provide the most favorable balance between efficacy and safety.
Although difelikefalin is a promising treatment option, current evidence remains limited, and additional well-designed randomized controlled trials are needed to confirm its effectiveness.
While most existing studies have been conducted in Western populations, data from low- and middle-income countries such as Bangladesh are limited. The prevalence of CKD in Bangladesh is high, affecting millions of individuals, with a significant number progressing to end-stage renal disease annually.
This study aims to evaluate the superiority of difelikefalin over placebo in reducing pruritus severity among patients undergoing maintenance hemodialysis in a tertiary-level teaching hospital in Bangladesh.
Chittagong Medical College is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Difelikefalin (0.5 mcg/kg) will be administered intravenously at the end of each hemodialysis session, three times per week, for a total duration of 6 weeks in patients with CKD-associated pruritus.
Drug: Difelikefalin Injection
Participants will receive intravenous normal saline at the end of each hemodialysis session, three times per week, for 6 weeks, administered in a volume equivalent to the difelikefalin dose
Drug: Normal Saline (0.9% NaCl)
ntravenous difelikefalin (κ-opioid receptor agonist) administered at a dose of 0.5 mcg/kg at the end of each hemodialysis session, three times weekly,for a total duration of 6 wks in patients undergoing maintenance hemodialysis with moderate to severe CKD -associated pruritus
Intravenous normal saline will be administered at the end of each hemodialysis session, three times per week, for a total duration of 6 weeks, in a volume equivalent to the difelikefalin dose.
Change From Baseline in Worst Itching Intensity Numerical Rating Scale (WI-NRS) Score at 6 Weeks
The Worst Itching Intensity Numerical Rating Scale (WI-NRS) is an 11-point scale ranging from 0 (no itching) to 10 (worst imaginable itching). The outcome will be reported as the mean change in WI-NRS score from baseline to week 6
Time frame: Baseline to Week 6
Change From Baseline in Skindex-10 Score at 6 Weeks
Skindex-10 is a validated questionnaire used to assess quality of life in patients with skin conditions. Scores range from 0 to 60, with higher scores indicating worse quality of life. The outcome will be reported as the mean change from baseline to week 6.
Time frame: Baseline to Week 6
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — Individual participant data (IPD) will not be shared due to privacy and confidentiality concerns, as well as institutional and ethical restrictions
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chittagong Medical College